Plus Therapeutics Secures CPT Code for REYOBIQ Delivery in Brain Cancer Treatments
Event summary
- Plus Therapeutics received a new Category III CPT code for convection-enhanced delivery (CED) used with REYOBIQ in recurrent glioblastoma (rGBM) and pediatric brain cancer (PBC).
- The new CPT code (X566T) will be effective for reporting starting January 1, 2027.
- REYOBIQ is a novel injectable radiotherapy designed for CNS tumors, currently in Phase 2 trials for rGBM and planned Phase 1 trials for PBC.
- Plus Therapeutics expects to complete enrollment in its Phase 2 rGBM trial in 2026 and begin Phase 1 PBC trial enrollment in 2026.
The big picture
The approval of a new CPT code for REYOBIQ's delivery method is a critical step in Plus Therapeutics' strategy to commercialize its radiopharmaceutical for CNS cancers. This development aligns with broader industry trends toward precision medicine and targeted therapies, particularly for aggressive and hard-to-treat cancers like glioblastoma. The company's progress in clinical trials, supported by significant grants from the NCI and CPRIT, underscores the growing investment in innovative cancer treatments. The strategic anomaly here is the dual focus on both adult and pediatric brain cancer, a niche that could position Plus Therapeutics as a key player in this underserved market.
What we're watching
- Commercialization Pathway
- How the new CPT code will facilitate market access and reimbursement for REYOBIQ, accelerating its adoption in rGBM and PBC treatments.
- Clinical Trial Progress
- The pace at which Plus Therapeutics completes enrollment in its Phase 2 rGBM trial and initiates the Phase 1 PBC trial, impacting REYOBIQ's regulatory approval timeline.
- Reimbursement Dynamics
- Whether the Category III CPT code will transition to a permanent Category I code, ensuring long-term reimbursement stability for REYOBIQ.
Related topics